Oncotelic Therapeutics (OTCQB: OTLC) announced that three abstracts featuring its investigational intravenous Deciparticle (TM) everolimus (Sapu003) have been accepted for presentation at the 2025 San Antonio Breast Cancer Symposium, to be held Dec. 9–12 in San Antonio, Texas. The abstracts collectively detail the clinical rationale, molecular biomarkers, and pharmacokinetic data supporting the ongoing Phase 1 trial in HR⁺/HER2⁻ metastatic breast cancer.
Sapu003 is a novel IV formulation of everolimus developed by Sapu Nano—a joint venture between Oncotelic and Dragon Oversea. It is designed to overcome the limitations of oral mTOR inhibitors such as Afinitor (R), including poor bioavailability and restricted tumor penetration. The acceptance of these abstracts at a major symposium underscores the potential significance of this approach in addressing unmet needs in breast cancer treatment.
For more details, the full press release is available at https://ibn.fm/Ut6V8. Oncotelic Therapeutics is a clinical-stage biopharmaceutical company focused on oncology and immunotherapy products, addressing high-unmet-need cancers and rare pediatric indications. The company leverages its PDAOAI platform and expertise in nanomedicines to develop transformative cancer therapies.
In addition to its directly owned pipeline, Oncotelic benefits from the robust portfolio of inventions created by its CEO, Dr. Vuong Trieu, who has filed more than 150 patent applications and holds 39 issued U.S. patents. The company also licenses and codevelops select drug candidates through joint ventures, including its 45% ownership of GMP Bio, which is advancing its own pipeline of drug candidates that complement Oncotelic’s strategic position in oncology and rare disease therapeutics.
Investors can stay updated with the latest news and updates relating to OTLC in the company’s newsroom at https://ibn.fm/OTLC. The San Antonio Breast Cancer Symposium is a premier annual conference for breast cancer research, and the acceptance of these abstracts highlights the potential impact of Sapu003 in improving outcomes for patients with HR⁺/HER2⁻ metastatic breast cancer.
